Association of Glutathione S-Transferase P1 (GSTP1) Gene Polymorphism with the Response to Platinum Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Abstract

ung cancer is a malignant lung tumor characterized by uncontrolled cell growth in the lung tissues. Lung cancer is currently both the most commonly diagnosed cancer (accounting for 11.4% of all cancer diagnoses) and the leading cause of cancer-related mortality (18% of overall cancer mortality) in both men and women worldwide. The two main types of lung cancer are small cell lung carcinoma and non-small-cell lung carcinoma. Non-small cell lung cancer accounts for 85% of all cases. Platinum-based chemotherapy is one of the major therapeutic methods for NSCLC, especially for advanced cancer. However, in clinical practice, the chemotherapy response varies wildly among individuals. Some patients respond to the chemotherapy, while others confer intrinsic or acquired resistance. It is speculated that some genetic polymorphisms may affect drug response, and there are accumulating evidences to support this hypothesis. Glutathione-S-Transferases (GSTs) are a family of Phase II detoxification enzymes that catalyses the conjugation of glutathione (GSH) to a wide variety of endogenous and exogenous electrophilic compounds -as cisplatin- for th